Asia
Haichang, at its own expense, will develop its updated RX-0201 through proof-of-concept in China.
Says the co will invest 150 million yuan to set up an investment fund with initial fund size of 250 million yuan.
Less than two months into the year, Teva’s new chief has already effectively written off a recovery for 2018.
It’s starting to feel like Teva can’t catch a break.
The cuts were apparently announced in late January with a WARN notice filed with the state.
Jing Medicine Technology will collaborate with ShanghaiTech University in a $100M partnership to discover and develop novel small molecule cancer drugs.
Luqa Pharma of Hong Kong closed a $15M Series B financing round led by Cenova Capital.
NetVation DL Medicine, a privately held Chengdu biotech, has entered a two-year research collaboration with Pfizer.
CR Pharma will be responsible for China clinical trials and other regulatory matters.
Late-stage data shows the use of Pfizer’s prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.
PRESS RELEASES